We are developing innovative first-in-class mechanobiology-based genetic medicines for genetically defined cardiomyopathies.
The complexity of genetic cardiomyopathies poses a formidable challenge. More than 30 gene mutations are known to underlie these conditions, with most being inherited autosomal dominantly, with a mutant copy of the gene causing disease. This renders traditional gene replacement approaches infeasible for many of these mutations.
Nuevocor, however, has charted a different course focused on the development of pathway-centric genetic medicines grounded in mechanobiology. This innovative approach enabled by our PrOSIA platform holds significant promise as it targets the common biomechanical pathways shared among multiple genetic cardiomyopathies. Importantly, it means that each therapeutic we create has the potential to treat multiple genetic cardiomyopathies, vastly expanding our capacity to reach and impact broader patient populations.
We are committed to treating genetic cardiomyopathies by advancing a pipeline of innovative pathway-centric genetic medicines that address the root cause of disease.
Nuevocor's core strength lies in our innovative PrOSIA mechanobiology platform. This cutting-edge technology gives us unprecedented insights into the causal biomechanical changes in cardiomyopathies. Our platform serves as the foundation upon which we design our novel pathway-centric genetic medicines, designed to tackle genetic cardiomyopathies at their root cause.
Leveraging our PrOSIA mechanobiology platform, we design genetic medicines to treat the underlying biomechanical root cause of disease. This pathway-centric approach enables us to go beyond traditional gene therapy, which treats single gene mutations. By treating pathways involved in the disease, each of our therapeutics can help a larger number of patients. We consider ourselves at the forefront of a new generation of genetic medicine companies pioneering such an innovative pathway-centric approach.
LMNA Dilated Cardiomyopathy
Nuevocor’s lead program NVC-001 is a genetic medicine to treat patients suffering lamin dilated cardiomyopathy. Dilated cardiomyopathy is a common cause of heart failure, characterized by enlargement of the left ventricle and a reduction in the ability of the heart to pump blood.
Lamin dilated cardiomyopathy is among the top 3 most common causes of genetic dilated cardiomyopathy and has the worst prognosis of all dilated cardiomyopathies, making it a serious and aggressive disease. Today, other than receiving a cardiac transplant, there are no effective treatments available. New and effective therapies are therefore urgently needed.
NVC-001 treats lamin dilated cardiomyopathy by addressing the biomechanical root cause of disease.